Epoch Investment Partners Inc. Sells 101,867 Shares of Bristol-Myers Squibb (NYSE:BMY)

Epoch Investment Partners Inc. decreased its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 8.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,059,239 shares of the biopharmaceutical company's stock after selling 101,867 shares during the period. Epoch Investment Partners Inc. owned 0.05% of Bristol-Myers Squibb worth $59,911,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Morse Asset Management Inc lifted its position in shares of Bristol-Myers Squibb by 25.0% during the 3rd quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock valued at $517,000 after buying an additional 2,000 shares during the last quarter. Tudor Financial Inc. purchased a new stake in Bristol-Myers Squibb during the third quarter valued at about $250,000. Pine Valley Investments Ltd Liability Co boosted its position in Bristol-Myers Squibb by 1.3% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company's stock worth $2,323,000 after purchasing an additional 575 shares during the period. World Investment Advisors LLC raised its position in shares of Bristol-Myers Squibb by 18.7% in the third quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company's stock valued at $2,282,000 after purchasing an additional 6,954 shares during the period. Finally, Arvest Bank Trust Division purchased a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at approximately $1,724,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,823 shares of Bristol-Myers Squibb stock in a transaction on Friday, February 14th. The stock was acquired at an average price of $54.84 per share, with a total value of $99,973.32. Following the acquisition, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.09% of the stock is owned by company insiders.

Bristol-Myers Squibb Stock Down 2.4 %

Shares of NYSE BMY traded down $1.15 on Friday, reaching $47.55. 8,943,549 shares of the company's stock traded hands, compared to its average volume of 13,061,529. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The company has a market cap of $96.74 billion, a price-to-earnings ratio of -10.75, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The business's 50 day simple moving average is $56.50 and its two-hundred day simple moving average is $56.50.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.55 by $0.25. The firm had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. During the same period in the prior year, the firm posted ($4.40) earnings per share. As a group, equities research analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.22%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's payout ratio is -56.11%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Cantor Fitzgerald restated a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday. Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a report on Tuesday. They issued an "overweight" rating and a $65.00 price target on the stock. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Jefferies Financial Group reduced their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.